TRIB3‒GSK-3

Author: Shanshan LIU ¹ ; Xiaoxi LV ¹ ; Xupeng WEI ² ; Chang LIU ¹ ; Qiao LI ³ ; Jiali MIN ³ ; Fang HUA ¹ ; Xiaowei ZHANG ¹ ; Ke LI ⁴ ; Pingping LI ¹ ; Yang XIAO ³ ; Zhuowei HU ¹ ; Bing CUI ¹
Author Information

1. State Key Laboratory of Bioactive Substance and Function of Natural Medicines, Institute of Materia Medica, CAMS Key Laboratory of Molecular Mechanism and Target Discovery of Metabolic Disorder and Tumorigenesis, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing 100050, China.
2. Department of Pharmacy, Pharmacy College, Hebei University, Baoding 071000, China.
3. National Clinical Research Center for Metabolic Diseases, Department of Metabolism and Endocrinology, the Second Xiangya Hospital, Central South University, Changsha 410011, China.
4. Institute of Medicinal Biotechnology, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing 100050, China.
Publication Type:Journal Article
Keywords: E3 ligase; GSK-3β; Lung injury; Protein phosphorylation; Protein–protein interaction; TRIB3; Ubiquitination
From: Acta Pharmaceutica Sinica B 2021;11(10):3105-3119
CountryChina
Language:English
Abstract: Pulmonary fibrosis (PF) is a chronic, progressive, fatal interstitial lung disease with limited available therapeutic strategies. We recently reported that the protein kinase glycogen synthase kinase-3